Rigel Pharmaceuticals, Inc.NASDAQ: RIGL

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

· Issued by Rigel Pharmaceuticals, Inc. via PR Newswire

Summary by 6ix AI

Rigel Pharmaceuticals, Inc., a biotechnology company developing therapies for blood disorders and cancer, granted 35,275 restricted stock units (rights to receive company shares over time) to 18 non-executive employees as an incentive for joining the company, as of October 2, 2026.

Key details

  • The units vest over four years, with 25% of the grant vesting each year.
  • The awards were made under the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors.
  • The grants were made under NASDAQ Listing Rule 5635(c)(4), the Nasdaq rule covering stock awards given to people as an inducement to join a company.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4

Watch Rigel Pharmaceuticals' latest callRigel Pharmaceuticals (NASDAQ:RIGL) Q3 2026 Earnings Call · Replay · Nov 5Read the transcript of Rigel Pharmaceuticals (NASDAQ:RIGL) Q3 2026 Earnings Call

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel's Board of Directors and granted as an inducement material to employees entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635(c)(4). Specifically, Rigel granted 35,275 restricted stock units to 18 non-executive employees vesting over four years with 25% of the grant vesting each year.

About RigelRigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. For more information on Rigel, its marketed products and pipeline of potential products, please visit www.rigel.com.

Contact for Investors & MediaRigel Pharmaceuticals, Inc. 650.624.1232ir@rigel.com

Rigel Pharmaceuticals Logo

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-pharmaceuticals-inc-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302896740.html

SOURCE Rigel Pharmaceuticals, Inc.

View original source (PR Newswire)Rigel Pharmaceuticals, Inc. on 6ix

Story so far

Earlier from Rigel Pharmaceuticals

Later from Rigel Pharmaceuticals

All Rigel Pharmaceuticals news releases